on INVENTIVA (EPA:IVA)
Inventiva to Participate in Guggenheim Biotech Summit 2026
Inventiva, a clinical-stage biopharmaceutical company based in Daix, France, will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026. The event takes place February 11-12, 2026, at the Lotte New York Palace, New York City. CEO Andrew Obenshain is scheduled for a fireside chat on February 11 at 1:00 pm (ET).
The company, traded on Euronext Paris and NASDAQ, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH). During the summit, Inventiva's leadership will also conduct one-on-one meetings. The company is actively evaluating lanifibranor in a Phase 3 trial for MASH treatment.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INVENTIVA news